Breaking News, Collaborations & Alliances

Dragonfly Therapeutics Expands Research Collaboration with Abbvie

Will discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, has expanded its research collaboration with AbbVie to discover and develop Dragonfly’s novel immunotherapies for new targets in autoimmune and fibrotic diseases.   AbbVie successfully licensed its first TriNKET drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in January 2021.   “AbbVie is committed...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters